These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1675 related articles for article (PubMed ID: 26686957)

  • 1. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
    Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Ganz PA; Cecchini RS; Julian TB; Margolese RG; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
    Lancet; 2016 Feb; 387(10021):857-65. PubMed ID: 26686960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
    Forbes JF; Sestak I; Howell A; Bonanni B; Bundred N; Levy C; von Minckwitz G; Eiermann W; Neven P; Stierer M; Holcombe C; Coleman RE; Jones L; Ellis I; Cuzick J;
    Lancet; 2016 Feb; 387(10021):866-73. PubMed ID: 26686313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
    Masuda N; Sagara Y; Kinoshita T; Iwata H; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Noguchi S
    Lancet Oncol; 2012 Apr; 13(4):345-52. PubMed ID: 22265697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
    Tjan-Heijnen VCG; van Hellemond IEG; Peer PGM; Swinkels ACP; Smorenburg CH; van der Sangen MJC; Kroep JR; De Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; de Boer M; de Roos WK; Linn SC; Imholz ALT; Seynaeve CM;
    Lancet Oncol; 2017 Nov; 18(11):1502-1511. PubMed ID: 29031778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
    Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
    Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
    Cuzick J; Sestak I; Forbes JF; Dowsett M; Knox J; Cawthorn S; Saunders C; Roche N; Mansel RE; von Minckwitz G; Bonanni B; Palva T; Howell A;
    Lancet; 2014 Mar; 383(9922):1041-8. PubMed ID: 24333009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
    Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
    Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
    Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H;
    J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
    Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
    J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
    Robertson JFR; Bondarenko IM; Trishkina E; Dvorkin M; Panasci L; Manikhas A; Shparyk Y; Cardona-Huerta S; Cheung KL; Philco-Salas MJ; Ruiz-Borrego M; Shao Z; Noguchi S; Rowbottom J; Stuart M; Grinsted LM; Fazal M; Ellis MJ
    Lancet; 2016 Dec; 388(10063):2997-3005. PubMed ID: 27908454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
    Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
    Buzdar AU;
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):399-403. PubMed ID: 14623537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Mamounas EP; Bandos H; Lembersky BC; Jeong JH; Geyer CE; Rastogi P; Fehrenbacher L; Graham ML; Chia SK; Brufsky AM; Walshe JM; Soori GS; Dakhil SR; Seay TE; Wade JL; McCarron EC; Paik S; Swain SM; Wickerham DL; Wolmark N
    Lancet Oncol; 2019 Jan; 20(1):88-99. PubMed ID: 30509771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
    Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R;
    Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
    De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
    Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
    Novoa Vargas A; Font López KC; Amador DD
    Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 84.